ArticleJournal of hematology & oncology2015
Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.
Article in Journal of hematology & oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.Breast cancer research and treatment · 2022Trial
- Male breast cancer: from extrapolated practice to evidence-based care.The oncologist · 2026Review
- Impact of adjuvant endocrine therapy utilization in male patients with early breast cancer: results from a large German real-world claims data analysis.Archives of gynecology and obstetrics · 2025Article
- Neoadjuvant treatment for male breast cancer.Translational cancer research · 2023Article
- Targeting Breast Cancer: An Overlook on Current Strategies.International journal of molecular sciences · 2023Review
- Endocrine adherence in male versus female breast cancer: a seer-medicare review.Breast cancer research and treatment · 2022Review
- Male Breast Cancer: An Updated Review of Epidemiology, Clinicopathology, and Treatment.Journal of oncology · 2022Review
- Management of Male Breast Cancer: The Journey so Far and Future Directions.World journal of oncology · 2021Review
- Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).Therapeutic advances in medical oncology · 2020Article
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.Expert review of anticancer therapy · 2019Review
- Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.Frontiers in oncology · 2019Review
- Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients.Innovations in pharmacy · 2019Article
- Surgical options for male breast cancer.Breast cancer research and treatment · 2018Review
- Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression.Scientific reports · 2017Article
- Recent advances of highly selective CDK4/6 inhibitors in breast cancer.Journal of hematology & oncology · 2017Review
- Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.The oncologist · 2016Article
- Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.Cancer research and treatment · 2016Article
- The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.The Journal of steroid biochemistry and molecular biology · 2016Review
- Male breast cancer - a single center experience.Oncology letters · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting.
methodsWe herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients).
resultsOverall response rate was 43.5% in patients treated with monotherapy and 51.3% with combination therapy (p = 0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p = 0.05), 1-year progression-free survival rate (43.2% versus 21.7%; p = 0.05), median overall survival (29.7 months versus 22 months; p = 0.05), and 2-year survival rate (64.9% versus 43.5%; p = 0.05).
conclusionsIn metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.